Spoerl S, Kremer AN, Aigner M, et al. - Researchers herein sought the underlying reasons why a smaller percentage of patients with COVID‐19 present with severe pulmonary symptoms whereas the majority is only mildly affected. They compared the immunological phenotype in healthy donors and patients with mild vs severe COVID‐19 and identified enhanced NK‐/B‐cell activation and proliferation in COVID‐19 patients, independent of severity. As an important precondition for effective antibody responses, patients with mild and severe SARS‐CoV‐2 infection both had an increase in T‐follicular helper cells and antibody secreting cells. In COVID‐19 patients, T cells in addition show a stronger activation profile with differentiation toward effector cell phenotypes. Importantly, when considering the rates of pulmonary complications in COVID‐19 patients, both CD4 and CD8 T cells of patients with severe COVID‐19 show higher expression of the chemokine receptor CCR4. Based on this, they hypothesize that CCR4 upregulation on T cells in the pathogenesis of COVID‐19 promotes stronger T‐cell attraction to the lungs resulting in enhanced immune activation with presumably higher pulmonary toxicity. These findings may provide significant contribution to the understanding of the immunological changes during COVID‐19, as new therapeutic agents, preferentially targeting the immune system, are highly warranted.